newsfilter
← Latest News
GlobeNewswire·

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment